Prognostic factors for survival in patients with mucosal and ocular melanoma treated with ipilimumab: Turkish Oncology Group study

Yasar H. A., Turna H., Esin E., Sedef A. M., Alkan A., Oksuzoglu B., ...Daha Fazla

JOURNAL OF ONCOLOGY PHARMACY PRACTICE, cilt.26, sa.2, ss.267-272, 2020 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 26 Sayı: 2
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1177/1078155219840796
  • Dergi Adı: JOURNAL OF ONCOLOGY PHARMACY PRACTICE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, Agricultural & Environmental Science Database, CINAHL, EMBASE, International Pharmaceutical Abstracts, MEDLINE
  • Sayfa Sayıları: ss.267-272
  • Anahtar Kelimeler: Ipilimumab, uveal melanoma, mucosal melanoma, prognostic factors, UVEAL MELANOMA, PEMBROLIZUMAB, BRACHYTHERAPY, MUTATIONS, OUTCOMES, NIVOLUMAB, TRENDS, KIT
  • Ankara Üniversitesi Adresli: Evet

Özet

Objective